Comparative gene expression profiles induced by PPARγ and PPARα/γ agonists in human hepatocytes

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Rogue, Alexandra ^a,b,c   Lambert, Carine ^a,b   Jossé, Rozenn ^a,b   Antherieu, Sebastien ^a,b   Spire, Catherine ^c   Claude, Nancy ^c   Guillouzo, André ^a,b  

^a FACULTÉ DES SCIENCES PHARMACEUTIQUES ET BIOLOGIQUES   (France)

^b UNIVERSITÉ DE RENNES 1   (France)

^c INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MURAGLITAZAR; ROSIGLITAZONE; TESAGLITAZAR; TRANSCRIPTOME; TROGLITAZONE; ADENOSINE TRIPHOSPHATE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; REACTIVE OXYGEN METABOLITE;

ADULT; ARTICLE; CELL POPULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG EXPOSURE; DRUG RESPONSE; FEMALE; GENE CONTROL; GENE EXPRESSION PROFILING; HEPATOMA CELL; HUMAN; HUMAN CELL; LIVER CELL; UPREGULATION; CELL CULTURE; CLUSTER ANALYSIS; DRUG POTENTIATION; METABOLISM; POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADENOSINE TRIPHOSPHATE; ADULT; BLOTTING, WESTERN; CELLS, CULTURED; CLUSTER ANALYSIS; GENE EXPRESSION PROFILING; HEPATOCYTES; HUMANS; POLYMERASE CHAIN REACTION; PPAR ALPHA; PPAR GAMMA; REACTIVE OXYGEN SPECIES;

EID: 79955138219     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0018816     Document Type: Article

References (42)

1. Feige JN, Gelman L, Michalik L, Desvergne B, Wahli W, (2006) From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog Lipid Res 45: 120-159.
2. Michalik L, Auwerx J, Berger JP, Chatterjee VK, Glass CK, et al. (2006) International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev 58: 726-741.
3. Staels B, Fruchart JC, (2005) Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 54: 2460-2470.
4. Guo L, Zhang L, Sun Y, Muskhelishvili L, Blann E, et al. (2006) Differences in hepatotoxicity and gene expression profiles by anti-diabetic PPAR gamma agonists on rat primary hepatocytes and human HepG2 cells. Mol Divers 10: 349-360.
5. Fievet C, Fruchart JC, Staels B, (2006) PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome. Curr Opin Pharmacol 6: 606-614.
6. Yang Q, Nagano T, Shah Y, Cheung C, Ito S, et al. (2008) The PPAR alpha-humanized mouse: a model to investigate species differences in liver toxicity mediated by PPAR alpha. Toxicol Sci 101: 132-139.
7. Klaunig JE, Babich MA, Baetcke KP, Cook JC, Corton JC, et al. (2003) PPARalpha agonist-induced rodent tumors: modes of action and human relevance. Crit Rev Toxicol 33: 655-780.
8. Guillouzo A, (1998) Liver cell models in in vitro toxicology. Environ Health Perspect 106 (Suppl 2): 511-532.
9. Aninat C, Piton A, Glaise D, Le Charpentier T, Langouet S, et al. (2006) Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells. Drug Metab Dispos 34: 75-83.
10. Josse R, Aninat C, Glaise D, Dumont J, Fessard V, et al. (2008) Long-term functional stability of human HepaRG hepatocytes and use for chronic toxicity and genotoxicity studies. Drug Metab Dispos 36: 1111-1118.
11. Guguen-Guillouzo C, Campion JP, Brissot P, Glaise D, Launois B, et al. (1982) High yield preparation of isolated human adult hepatocytes by enzymatic perfusion of the liver. Cell Biol Int Rep 6: 625-628.
12. Gripon P, Rumin S, Urban S, Le Seyec J, Glaise D, et al. (2002) Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci U S A 99: 15655-15660.
13. Cerec V, Glaise D, Garnier D, Morosan S, Turlin B, et al. (2007) Transdifferentiation of hepatocyte-like cells from the human hepatoma HepaRG cell line through bipotent progenitor. Hepatology 45: 957-967.
14. Brazma A, Hingamp P, Quackenbush J, Sherlock G, Spellman P, et al. (2001) Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat Genet 29: 365-371.
15. Jigorel E, Le Vee M, Boursier-Neyret C, Bertrand M, Fardel O, (2005) Functional expression of sinusoidal drug transporters in primary human and rat hepatocytes. Drug Metab Dispos 33: 1418-1422.
16. Gould Rothberg BE, Sundseth SS, DiPippo VA, Brown PJ, Winegar DA, et al. (2001) The characterization of PPAR alpha ligand drug action in an in vivo model by comprehensive differential gene expression profiling. Funct Integr Genomics 1: 294-304.
17. Rakhshandehroo M, Hooiveld G, Muller M, Kersten S, (2009) Comparative analysis of gene regulation by the transcription factor PPARalpha between mouse and human. PLoS One 4: e6796.
18. Mandard S, Muller M, Kersten S, (2004) Peroxisome proliferator-activated receptor alpha target genes. Cell Mol Life Sci 61: 393-416.
19. Lambert CB, Spire C, Claude N, Guillouzo A, (2009) Dose- and time-dependent effects of phenobarbital on gene expression profiling in human hepatoma HepaRG cells. Toxicol Appl Pharmacol 234: 345-360.
20. Yamamoto Y, Nakajima M, Yamazaki H, Yokoi T, (2001) Cytotoxicity and apoptosis produced by troglitazone in human hepatoma cells. Life Sci 70: 471-482.
21. Isley WL, (2003) Hepatotoxicity of thiazolidinediones. Expert Opin Drug Saf 2: 581-586.
22. Shishido S, Koga H, Harada M, Kumemura H, Hanada S, et al. (2003) Hydrogen peroxide overproduction in megamitochondria of troglitazone-treated human hepatocytes. Hepatology 37: 136-147.
23. Feinstein DL, Spagnolo A, Akar C, Weinberg G, Murphy P, et al. (2005) Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key? Biochem Pharmacol 70: 177-188.
24. Ericsson H, Hamren B, Bergstrand S, Elebring M, Fryklund L, et al. (2004) Pharmacokinetics and metabolism of tesaglitazar, a novel dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist, after a single oral and intravenous dose in humans. Drug Metab Dispos 32: 923-929.
25. Goyak KM, Johnson MC, Strom SC, Omiecinski CJ, (2008) Expression profiling of interindividual variability following xenobiotic exposures in primary human hepatocyte cultures. Toxicol Appl Pharmacol 231: 216-224.
26. DeLuca JG, Doebber TW, Kelly LJ, Kemp RK, Molon-Noblot S, et al. (2000) Evidence for peroxisome proliferator-activated receptor (PPAR)alpha-independent peroxisome proliferation: effects of PPARgamma/delta-specific agonists in PPARalpha-null mice. Mol Pharmacol 58: 470-476.
27. Sahi J, Hamilton G, Sinz M, Barros S, Huang SM, et al. (2000) Effect of troglitazone on cytochrome P450 enzymes in primary cultures of human and rat hepatocytes. Xenobiotica 30: 273-284.
28. Kanebratt KP, Andersson TB, (2008) HepaRG cells as an in vitro model for evaluation of cytochrome P450 induction in humans. Drug Metab Dispos 36: 137-145.
29. Lauer B, Tuschl G, Kling M, Mueller SO, (2009) Species-specific toxicity of diclofenac and troglitazone in primary human and rat hepatocytes. Chem Biol Interact 179: 17-24.
30. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, et al. (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 270: 12953-12956.
31. Devasthale PV, Chen S, Jeon Y, Qu F, Shao C, et al. (2005) Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious glucose and lipid-lowering activities. J Med Chem 48: 2248-2250.
32. Hellmold H, Zhang H, Andersson U, Blomgren B, Holland T, et al. (2007) Tesaglitazar, a PPARalpha/gamma agonist, induces interstitial mesenchymal cell DNA synthesis and fibrosarcomas in subcutaneous tissues in rats. Toxicol Sci 98: 63-74.
33. Nissen SE, Wolski K, Topol EJ, (2005) Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 294: 2581-2586.
34. Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, Ali F, Sholley C, et al. (2010) Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 304: 411-418.
35. Stienstra R, Saudale F, Duval C, Keshtkar S, Groener JE, et al. (2010) Kupffer cells promote hepatic steatosis via interleukin-1beta-dependent suppression of peroxisome proliferator-activated receptor alpha activity. Hepatology 51: 511-522.
36. Scott MJ, Chen C, Sun Q, Billiar TR, (2010) Hepatocytes express functional NOD1 and NOD2 receptors: a role for NOD1 in hepatocyte CC and CXC chemokine production. J Hepatol 53: 693-701.
37. Camps L, Reina M, Llobera M, Bengtsson-Olivecrona G, Olivecrona T, et al. (1991) Lipoprotein lipase in lungs, spleen, and liver: synthesis and distribution. J Lipid Res 32: 1877-1888.
38. Jennen DG, Magkoufopoulou C, Ketelslegers HB, van Herwijnen MH, Kleinjans JC, et al. (2010) Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci 115: 66-79.
39. Antherieu S, Chesne C, Li R, Camus S, Lahoz A, et al. (2010) Stable expression, activity, and inducibility of cytochromes P450 in differentiated HepaRG cells. Drug Metab Dispos 38: 516-525.
40. Funk C, Pantze M, Jehle L, Ponelle C, Scheuermann G, et al. (2001) Troglitazone-induced intrahepatic cholestasis by an interference with the hepatobiliary export of bile acids in male and female rats. Correlation with the gender difference in troglitazone sulfate formation and the inhibition of the canalicular bile salt export pump (Bsep) by troglitazone and troglitazone sulfate. Toxicology 167: 83-98.
41. Anwer MS, (2004) Cellular regulation of hepatic bile acid transport in health and cholestasis. Hepatology 39: 581-590.
42. Malik AH, Prasad P, Saboorian MH, Thiele DL, Malet PF, (2000) Hepatic injury due to troglitazone. Dig Dis Sci 45: 210-214.